-
, or mechanotransduction signaling (e.g. YAP/TAZ, integrin, or intermediate-filament pathways) is advantageous. Ability to design and interpret experiments targeting the molecular determinants
-
targeted and biocompatible manner makes them promising vehicles for drug delivery, immune modulation, and precision oncology. The successful candidate should: Hold a Ph.D. or its equivalent, awarded within
-
hyperactivation of growth-controlling signalling pathways reshapes cellular signalling networks and influences the response of malignant melanoma to immunotherapy and targeted therapy with BRAF and MEK inhibitors
-
-related defects and their therapeutic targeting, is insufficient. The successful candidate will join the Laboratory of Cilia and Centrosome Biology (headed by Dr. Lukáš Čajánek) at Masaryk University in